H11.012
Amyloid pterygium of left eye
Clinical Classification Guidelines
Medical Intelligence & Overview
Amyloid pterygium of the left eye is a rare eye condition involving the growth of a thick, abnormal tissue on the conjunctiva, which is the clear tissue covering the white part of the eye. This growth is characterized by the accumulation of amyloid proteins, leading to a distinctive pterygium—a wing-shaped tissue extension that can slow or distort vision if left untreated. While pterygiums are often caused by environmental factors, the amyloid form has a unique underlying pathology that warrants special attention and management.
Causes & Symptoms
Clinical Causes: Accumulation of amyloid proteins in the conjunctiva tissue, possibly due to local or systemic amyloidosis. Chronic exposure to ultraviolet (UV) light, leading to tissue irritation and abnormal protein deposits. Genetic predisposition or familial tendencies in rare cases. Environmental factors such as dust, wind, and dry climates that cause eye irritation. Previous eye trauma or inflammation that may predispose to abnormal tissue growth. Underlying systemic amyloidosis, a condition with abnormal protein deposits affecting multiple organs.
Key Symptoms: A visible, wing-shaped growth extending onto the cornea, typically on the inner side of the left eye. Blurred or decreased vision if the growth encroaches upon the cornea or obstructs the visual axis. Redness, irritation, or dryness of the affected eye. A feeling of eye grittiness or having a foreign body sensation. Possible cosmetic concerns due to the noticeable tissue growth. In some cases, the growth remains asymptomatic and is discovered during routine eye exams.
Diagnostic & Treatment
Diagnosis Path: The diagnosis begins with a comprehensive eye examination, where an eye care professional inspects the conjunctiva and cornea. Slit-lamp microscopy provides detailed visualization of the tissue growth and its extent. Confirmatory tests may include biopsy of the lesion to identify amyloid deposits using special staining techniques like Congo red stain under polarized light. Additional systemic evaluation may be recommended if systemic amyloidosis is suspected, which involves blood tests, biopsy of other tissues, and imaging studies to assess for amyloid deposits elsewhere.
Treatment Protocols: Management strategies focus on preventing vision impairment and addressing cosmetic or discomfort concerns. These include: - **Observation:** Regular monitoring if the growth is small, asymptomatic, and not affecting vision. - **Surgical excision:** Removal of the amyloid pterygium may be indicated if it progresses, causes symptoms, or threatens vision. The procedure involves carefully excising the growth, with attention to minimize recurrence. - **Recurrence prevention:** Adjunctive therapies like conjunctival autografting or the application of mitomycin C may lower the chances of regrowth. - **Managing systemic amyloidosis:** If systemic involvement is identified, appropriate medical management by specialists will be necessary. Follow-up care after surgery typically includes monitoring for recurrence, managing inflammation, and maintaining ocular health through regular eye exams.
Clinical Advice & FAQs
Billing Guidance
Is H11.012 a billable ICD-10 code?
Yes, H11.012 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H11.012?
Clinical documentation must specify the nature of Amyloid pterygium of left eye and any associated comorbidities for accurate reporting.
Cite this Clinical Reference